NCT02226146已完成2 期
An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Number of Participants With Anti-Drug Antibodies
研究概览
简要总结
This is an open-label, proof-of-concept, single group study in adult participants with newly diagnosed, moderate to extensive BP.
详细描述
This is an open-label, proof-of-concept, single group study in adult patients with newly diagnosed, moderate to extensive BP.
The study will consist of three periods: a screening period of up to 2 weeks, an open-label treatment period lasting 4 weeks consisting of IV infusion of bertilimumab on Days 0 and 14 and Day 28, and a safety and efficacy follow-up period of approximately 13 weeks.
Patients will receive concomitant oral steroids during the treatment and follow-up period. They will start on 30 mg prednisone daily (or equivalent). The initial dose will be maintained for at least 1 week, commencing on Day 0, until blister formation has ceased, crusts and erosions have disappeared and reepithelialization of lesions has started. The corticosteroid dose will then be reduced to 20 mg daily for 5 to 14 days. According to clinical response, this will be followed by corticosteroid dose reduction in 5 mg steps every 5 to 14 days until a dose of 10 mg daily is reached and then corticosteroid dose reduction in 2.5 mg steps every 5 to 14 days until the end of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or females, ≥ 60 years of age.
- •Karnofsky performance status > 60%
- •Newly diagnosed, Bullous Pemphigoid per standard diagnostic criteria:
- •Clinical presentation [2]
- •Skin biopsy from a fresh blister showing subepidermal clefting and an inflammatory infiltrate consisting mainly of eosinophils
- •Immunofluorescence (IF) studies performed on uninvolved skin collected approximately 1 cm away from a fresh blister showing linear deposition of IgG and/or C3 along the basement membrane zone.
- •Moderate to extensive Bullous Pemphigoid defined by the mean number of new bullae and urticarial plaques that have appeared over the course of 3 days as determined by the investigator or referring physician (moderate disease defined by > 1 and ≤ 10 new bullae daily and ≥ 5 urticarial plaques and extensive disease by >10 new bullae daily) [3].
- •Adequate cardiac, renal and hepatic function as determined by the Investigator and demonstrated by screening laboratory evaluations, vital sign measurement, ECG recording and physical examination results.
- •Females of childbearing potential must agree to use effective contraception consistently throughout the study (such as hormonal contraception or two forms of barrier contraception) and have a negative serum pregnancy test at screening and a negative urine pregnancy test per the schedule of visits. Women are considered post-menopausal and not of childbearing potential if they have had 12 months of amenorrhea or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks previously.
- •Males must have had a vasectomy or have expressed that they have no interest in fertility in the future.
- •Fertile males must agree to use effective contraception consistently throughout the study and for a period of four months following the end of study drug administration.
- •Willing and able to adhere to the study visit schedule and other protocol requirements.
- •Willing and able to provide voluntary written informed consent or written informed consent from a legally authorized representative with assent from the patient.
- •Exclusion criteria:
- •Patients with severe medical or surgical conditions at screening or baseline including, but not limited to, severe dementia or mental impairment, severe stroke, severe cardiac insufficiency, severe arterial hypertension, severe or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, psychiatric, or any other severe acute or chronic medical condition that may increase the risk associated with study participation/treatment or may interfere with the interpretation of study results and, in the Investigator's opinion, would make the patient inappropriate for study entry.
- •Presence of any malignancy that has been under active treatment (e.g., radiotherapy or chemotherapy) within the 2 years prior to baseline or is anticipated to require treatment during the study period (including follow up) with the exception of patients with removal of uncomplicated basal cell carcinoma or cutaneous squamous cell carcinoma, who may take part in the study.
- •Congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, organ transplantation).
- •Clinically significant vital sign measurements or ECG findings as determined by the Investigator.
- •Clinically significant abnormal laboratory test results, unless regarded by the Investigator as related to BP, including but not limited to:
- •Hemoglobin level <10.0 g/dL
- •White blood cell count < 3 x 103/μL
- •Lymphocyte count < 0.5 x 103/μL
- •Platelet count <100 x 103/μL or >1200 x 103/μL
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 the upper limit of normal (ULN)
- •Alkaline phosphatase >3 ULN
- •Serum creatinine >2 ULN
- •Patients with mild, relapsed or refractory Bullous Pemphigoid. Mild disease defined by the mean number of new lesions that have appeared over the course of 3 days as determined by the investigator or referring physician, as follows: ≤ 1 bulla or < 5 urticarial plaques.
- •Concomitant skin conditions preventing physical evaluation of Bullous Pemphigoid.
- •Active or recent history of clinically significant infection within 1 month of baseline.
- •Pregnant or breast-feeding, or planning to become pregnant during the study.
- •Participation in a clinical trial of an investigational (unapproved) product within 4 weeks of baseline.
- •Known hypersensitivity to bertilimumab or any of the drug excipients.
- •Use of prednisone or other systemic steroids (excluding inhaled or ocular use of steroids) within 4 weeks prior to baseline. (Concomitant oral corticosteroids administered as part of the study protocol, from Day 0 onward, are allowed). Use of class 1 and 2 topical steroids (such as clobetasol propionate cream, reference Appendix D for further guidance) within 4 weeks prior to baseline. (Use of other topical steroids is allowed throughout the study at the discretion of the investigator).
- •Treatment with immunosuppressants (e.g., azathioprine, methotrexate) within 4 weeks prior to baseline.
- •Treatment with biologics (e.g., etanercept, adalimumab, ustekinumab, infliximab, intravenous Ig) within 4 months of baseline. Patients who have received rituximab within 1 year of baseline will be excluded from study participation.
- •Treatment with macrolides or tetracyclines within 4 weeks prior to baseline.
- •Received a vaccine or other immunostimulator within 4 weeks prior to baseline. Subject has current clinical, radiographic or laboratory evidence of active mycobacterium tuberculosis (TB) infection or prior evidence of active TB that, in the opinion of the investigator, has not been adequately treated or controlled and that represents a reactivation risk. If in the investigator's opinion the patient is at risk for latent TB, the patient should be evaluated for active/latent TB as applicable (e.g. PPD, QFT, and/or chest x-ray).
- •18. Evidence of an active disease of hepatitis B (HBsAg positive or HBcAb positive) or hepatitis C (HCV ab positive), CMV (IgM positive) or human immunodeficiency virus (HIV) infection (HIV1/2 Ab positive
- •Active abuse of alcohol or drugs.
- •Any other condition, which in the opinion of the Investigator would place the patient at an unacceptable risk if participating in the study protocol.
排除标准
- 未提供
研究组 & 干预措施
Bertilimumab
Experimental
Intravenous injection over 30 minutes of 10 mg/kg of Bertilimumab in physiological solution (PBS)
干预措施: Bertilimumab (Biological)
结局指标
主要结局
Number of Participants With Anti-Drug Antibodies
时间窗: Baseline up to 1 year
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
时间窗: Baseline up to 1 year
An AE is any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with the study treatment. TEAEs were defined as AEs that started on or after the first administration of study drug until the end of the follow up period. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'.
次要结局
- Number of Participants Who Achieved at Least 50%, 70% and 90% Reduction From Baseline in Total Activity Score of the Bullous Pemphigoid Disease Area Index (BPDAI) Score(Baseline, Day 84)
- Number of Participants Who Had Tapered to Prednisone Dose of ≤ 10 mg/Day(Baseline, Day 84)
- Percentage of Reduction From Baseline in BPDAI Pruritis (Visual Analogue Scale [VAS]) Total Score(Baseline, Day 84)
- Percentage of Reduction From Baseline in Autoimmune Bullous Diseases Quality of Life (ABQOL) Total Score(Baseline, Day 84)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
MRG-001 in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisLou Gehrig DiseaseMotor Neuron AtrophyMotor Neuron DiseaseNCT06315608MedRegen LLC10
已完成
2 期
Evaluate SAGE-547 in Female Participants With Severe Postpartum DepressionPostpartum DepressionNCT02285504Supernus Pharmaceuticals, Inc.4
招募中
早期 1 期
WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal AntibodyAdvanced Lung CancerNCT06106152Second Affiliated Hospital, School of Medicine, Zhejiang University20
招募中
2 期
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease PatientsMild, Moderate, or Severe Alzheimer's DiseaseNCT06745583Elixiron Immunotherapeutics Inc.15
招募中
不适用
UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple MyelomaNCT06279026PersonGen BioTherapeutics (Suzhou) Co., Ltd.15